However, there are seven antisense oligonucleotide drugs in clinical trials for cancer with the most advanced being Danvatirsen (AZD9150/IONIS-STAT3-2.5RX) for treatment of lymphoma and lung cancer, which reduces its target, STAT3, lowering IL-6 in the serum and reducing tumour burden (Hong et al., 2015; Reilley et al., 2018). Here, STAT3 is linked to neoplasm.